Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/216042
Title: Collaborative permeation of drug and excipients in transdermal formulations. In vitro scrutiny for ethanol: limonene combinations
Author: Boix Montañés, Antonio de Pádua
Celma-Lezcano, Carles
Obach Vidal, Rosendo
Peraire i Guitart, Concepció
Keywords: Medicació transdèrmica
Benzodiazepines
Transdermal medication
Benzodiazepines
Issue Date: 13-Nov-2022
Publisher: Elsevier B.V.
Abstract: Enhancement of skin permeation of drugs is affected by the simultaneous co-permeation of excipients that hinder the predictivity of in vitro tests. The collaborative effects of two permeation enhancers (ethanol and d-limonene) of a lipophilic drug (alprazolam) have been simultaneously assessed in human skin under different in vitro conditions: integrated setups of diffusion cell experiments with selective concentration gradients of permeants (asymmetric) or without (symmetric) have been combined with coadministration dosages (all-in-one) at different concentrations or short-time skin pretreatment to scrutiny this mutual performance. Findings: Drug permeation is increased under moderated supersaturation but reaches a stationary level above 33 % of its solubility. Ethanol in absence of a concentration gradient increases ca.5 times basal drug permeation. Limonene until 20 % permeates human skin proportionally to its donor concentration but its effect does not depend on ethanol in symmetric conditions and is based on skin imbibition rather than on a carry-on effect. Simultaneous permeation of ethanol and limonene reaches a stationary state after 1.5 h, enough time to achieve maximal enhancement of alprazolam permeation. Additive enhancement is based on ethanol solubilisation maximized by skin saturation of terpene. Complementary analyses of skin disruption published in the literature are in line with these assessments and consolidate them.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.ejpb.2022.11.004
It is part of: European Journal of Pharmaceutics and Biopharmaceutics, 2022, vol. 181, p. 239-248
URI: https://hdl.handle.net/2445/216042
Related resource: https://doi.org/10.1016/j.ejpb.2022.11.004
ISSN: 0939-6411
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
259779.pdf1.37 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons